This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Study Number

4795025

Phase

Age Group

Adult

Principal Investigator

Purpose

This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma

Check your eligibility for this trial

Check now

Full Title

A Phase 1 Open-label, Multicenter Study of LTZ-301 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

ClinicalTrials.Gov ID

NCT07121946

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.